Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • R&D
  • Product KT-110
  • Partners
  • News
  • Contact us

Kinnov Therapeutics CEO

20 years expertise in Med Chem.
Founder and Manager of Greenpharma
Is author of more than 50 scientific publications and 20 patents.

Dr Philippe BERNARD
kinnov February 8, 2020February 19, 2020 equipe
  • ← Kinnov Therapeutics raised 2.5 M€ for Phase 2 study of KT-110 on alcohol addiction
  • Emmanuel de RIVOIRE →

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, enters phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Company
  • Contact us
  • Home
  • Partners
  • Preclinical trials
  • Product KT-110
  • R&D
  • Vous avez des patients reconnus comme alcooliques ?
  • Vous voulez lever le pied sur votre consommation d’alcool ?

Copyright 2020 - Kinnov Therapeutics